DRI Healthcare Trust (DHT-UN) Q4 2024 earnings summary

Executive summary

• Achieved record financial results in 2024, with Normalized Total Cash Receipts rising 45% year-over-year to $190 million, driven by strong portfolio execution, capital deployment, and portfolio expansion.

• Completed four major royalty transactions in 2024, deploying $290.3 million and committing up to $457 million, enhancing portfolio duration and diversification.

• Remediated previously identified material weaknesses in governance and internal controls, with strengthened management and independent leadership.

• Expanded credit facilities to $632 million and improved cost of capital, positioning for continued growth.

• Returned $24.4 million to unit holders via distributions and unit repurchases, with an increased quarterly distribution announced for 2025.

Financial highlights

• Normalized Total Cash Receipts reached $190 million, up 45% year-over-year.

• Total income was $187.5 million, a 13% increase over 2023.

• Adjusted EBITDA was $156.6 million, up 37% year-over-year, with an 82% margin.

• Adjusted cash earnings per unit were $2.18; cash distributions declared at $0.34 per unit.

• Net Loss per Unit was $0.06 for 2024, compared to Net Earnings per Unit of $1.72 in 2023.

Outlook and guidance

• 2025 royalty income guidance set at $172–$182 million, excluding one-time items and new deals.

• Long-term CAGR guidance raised to high single-digit growth through 2030, base year 2022.

• Capital deployment target of $1.25 billion by end of 2025, with $1.07 billion already deployed and $207 million committed.

• Increased quarterly distribution to $0.10 per unit starting Q1 2025.